TrialBone marrow transplantation2017

An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial.

A Grigg et al.PubMed ↗Publisher ↗

No numbers read from the abstract.